Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Thornton

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Biology Direct|February 23, 2007
Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomasShuyu Li, Mark Phong, Michael Lahn, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancerMartin J Edelman, David R Gandara, Petr Hausner, et al.
Neuro-Oncology|February 13, 2010
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomasTeri N Kreisl, Svetlana Kotliarova, John A Butman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancerMatthew D Galsky, Nicholas J Vogelzang, Paul Conkling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A phase I trial of enzastaurin in patients with recurrent gliomasTeri N Kreisl, Lyndon Kim, Kraig Moore, et al.
Journal of Oncology|June 9, 2009
In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission TomographyKaren E Pollok, Michael Lahn, Nathan Enas, et al.
Targeted Oncology|June 8, 2017
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced CancerMichael Michael, Yung-Jue Bang, Young Suk Park, et al.
Urology|January 31, 2004
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of actionMario A Eisenberger, Menachem Laufer, Nicholas J Vogelzang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 daysJames P Stevenson, Weijing Sun, Maryann Gallagher, et al.
Investigational New Drugs|July 7, 2012
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokineticsNwabundo Nwankwo, Zhe Zhang, Ting Wang, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Biology Direct|February 23, 2007
Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomasShuyu Li, Mark Phong, Michael Lahn, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancerMartin J Edelman, David R Gandara, Petr Hausner, et al.
Neuro-Oncology|February 13, 2010
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomasTeri N Kreisl, Svetlana Kotliarova, John A Butman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancerMatthew D Galsky, Nicholas J Vogelzang, Paul Conkling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A phase I trial of enzastaurin in patients with recurrent gliomasTeri N Kreisl, Lyndon Kim, Kraig Moore, et al.
Journal of Oncology|June 9, 2009
In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission TomographyKaren E Pollok, Michael Lahn, Nathan Enas, et al.
Targeted Oncology|June 8, 2017
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced CancerMichael Michael, Yung-Jue Bang, Young Suk Park, et al.
Urology|January 31, 2004
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of actionMario A Eisenberger, Menachem Laufer, Nicholas J Vogelzang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 daysJames P Stevenson, Weijing Sun, Maryann Gallagher, et al.
Investigational New Drugs|July 7, 2012
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokineticsNwabundo Nwankwo, Zhe Zhang, Ting Wang, et al.
Pageof 2